PubRank

Significant geographical differences in prevalence of mutations associated with Plasmodium falciparum and Plasmodium vivax drug resistance in two regions from Papua New Guinea.

PubWeight™: 0.79‹?›

🔗 View Article (PMC 4600278)

Published in Malar J on October 09, 2015

Authors

Céline Barnadas1,2,3, Lincoln Timinao4, Sarah Javati5, Jonah Iga6, Elisheba Malau7,8, Cristian Koepfli9,10, Leanne J Robinson11,12,13, Nicolas Senn14,15, Benson Kiniboro16, Lawrence Rare17, John C Reeder18, Peter M Siba19, Peter A Zimmerman20, Harin Karunajeewa21,22, Timothy M Davis23, Ivo Mueller24,25,26

Author Affiliations

1: Vector Borne Diseases Unit, Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea. barnadas@wehi.edu.au.
2: Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia. barnadas@wehi.edu.au.
3: Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia. barnadas@wehi.edu.au.
4: Vector Borne Diseases Unit, Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea. lincoln.timinao@pngimr.org.pg.
5: Vector Borne Diseases Unit, Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea. sarah.javati@pngimr.org.pg.
6: Vector Borne Diseases Unit, Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea. jonah.iga@pngimr.org.pg.
7: Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia. malau@wehi.edu.au.
8: Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia. malau@wehi.edu.au.
9: Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia. koepfli@wehi.edu.au.
10: Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia. koepfli@wehi.edu.au.
11: Vector Borne Diseases Unit, Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea. robinson@wehi.edu.au.
12: Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia. robinson@wehi.edu.au.
13: Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia. robinson@wehi.edu.au.
14: Vector Borne Diseases Unit, Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea. nicolas.senn@gmail.com.
15: Swiss Tropical and Public Health Institute, Basel, Switzerland. nicolas.senn@gmail.com.
16: Vector Borne Diseases Unit, Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea. benson.kiniboro@pngimr.org.pg.
17: Vector Borne Diseases Unit, Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea. lawrence.rare@pngimr.org.pg.
18: Burnet Institute, Melbourne, Australia. reederj@who.int.
19: Vector Borne Diseases Unit, Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea. peter.siba@pngimr.org.pg.
20: Center for Global Health and Diseases, Case Western Reserve University, Cleveland, USA. paz@case.edu.
21: Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia. karunajeewa.h@wehi.edu.au.
22: Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia. karunajeewa.h@wehi.edu.au.
23: School of Medicine and Pharmacology, University of Western Australia, Perth, Australia. tim.davis@uwa.edu.au.
24: Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia. ivomueller@fastmail.fm.
25: Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia. ivomueller@fastmail.fm.
26: Centre de Recerca en Salut Internacional de Barcelona, Barcelona, Spain. ivomueller@fastmail.fm.

Articles citing this ↘

Geographic distribution of amino acid mutations in DHFR and DHPS in Plasmodium vivax isolates from Lao PDR, India and Colombia. Malar J (2016) 0.79

Genetic diversity of Plasmodium vivax metacaspase 1 and Plasmodium vivax multi-drug resistance 1 genes of field isolates from Mauritania, Sudan and Oman. Malar J (2017) 0.75

Measuring ex vivo drug susceptibility in Plasmodium vivax isolates from Cambodia. Malar J (2017) 0.75

Articles cited by this ↗

Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med (2014) 11.87

A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature (2013) 11.03

Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science (2002) 6.19

A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med (2008) 4.77

Plasmodium vivax resistance to chloroquine? Lancet (1989) 4.51

Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? Trends Parasitol (2001) 3.84

Chloroquine resistant Plasmodium vivax: in vitro characterisation and association with molecular polymorphisms. PLoS One (2007) 2.66

Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations. Antimicrob Agents Chemother (2002) 2.52

Evolution of a unique Plasmodium falciparum chloroquine-resistance phenotype in association with pfcrt polymorphism in Papua New Guinea and South America. Proc Natl Acad Sci U S A (2001) 2.41

Sequence variations in the Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene and their relationship with pyrimethamine resistance. Mol Biochem Parasitol (1998) 2.08

The epidemiology of malaria in Papua New Guinea. Trends Parasitol (2003) 2.03

Coartem (artemether-lumefantrine) in Africa: the beginning of the end? J Infect Dis (2005) 2.00

Differential patterns of infection and disease with P. falciparum and P. vivax in young Papua New Guinean children. PLoS One (2010) 1.87

Plasmodium vivax resistance to chloroquine in Madagascar: clinical efficacy and polymorphisms in pvmdr1 and pvcrt-o genes. Antimicrob Agents Chemother (2008) 1.86

Identification of the Plasmodium vivax mdr-like gene (pvmdr1) and analysis of single-nucleotide polymorphisms among isolates from different areas of endemicity. J Infect Dis (2004) 1.83

Development of a multiplex PCR-ligase detection reaction assay for diagnosis of infection by the four parasite species causing malaria in humans. J Clin Microbiol (2004) 1.80

Strategies for detection of Plasmodium species gametocytes. PLoS One (2013) 1.67

Occurrence of the Southeast Asian/South American SVMNT haplotype of the chloroquine-resistance transporter gene in Plasmodium falciparum in Tanzania. J Infect Dis (2006) 1.64

High sensitivity detection of Plasmodium species reveals positive correlations between infections of different species, shifts in age distribution and reduced local variation in Papua New Guinea. Malar J (2009) 1.62

Comparison of diagnostic methods for the detection and quantification of the four sympatric Plasmodium species in field samples from Papua New Guinea. Malar J (2010) 1.60

Low efficacy of amodiaquine or chloroquine plus sulfadoxine-pyrimethamine against Plasmodium falciparum and P. vivax malaria in Papua New Guinea. Am J Trop Med Hyg (2007) 1.58

Plasmodium vivax: allele variants of the mdr1 gene do not associate with chloroquine resistance among isolates from Brazil, Papua, and monkey-adapted strains. Exp Parasitol (2005) 1.58

Sulfadoxine resistance in Plasmodium vivax is associated with a specific amino acid in dihydropteroate synthase at the putative sulfadoxine-binding site. Antimicrob Agents Chemother (2004) 1.52

Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg (2014) 1.51

Multiplicity and diversity of Plasmodium vivax infections in a highly endemic region in Papua New Guinea. PLoS Negl Trop Dis (2011) 1.47

Analysis of the Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene sequence. Gene (1998) 1.37

Studies on the epidemiology of malaria in New Guinea. Part I. Holoendemic malaria--the clinical picture. Trans R Soc Trop Med Hyg (1960) 1.36

Molecular markers of in vivo Plasmodium vivax resistance to amodiaquine plus sulfadoxine-pyrimethamine: mutations in pvdhfr and pvmdr1. J Infect Dis (2008) 1.26

Plasmodium falciparum drug resistance phenotype as assessed by patient antimalarial drug levels and its association with pfmdr1 polymorphisms. J Infect Dis (2012) 1.26

Analysis of single-nucleotide polymorphisms in the crt-o and mdr1 genes of Plasmodium vivax among chloroquine-resistant isolates from the Brazilian Amazon region. Antimicrob Agents Chemother (2009) 1.18

Three different Plasmodium species show similar patterns of clinical tolerance of malaria infection. Malar J (2009) 1.09

Role of pfmdr1 mutations on chloroquine resistance in Plasmodium falciparum isolates with pfcrt K76T from Papua New Guinea. Acta Trop (2006) 1.07

Characterization of treatment failure in efficacy trials of drugs against Plasmodium vivax by genotyping neutral and drug resistance-associated markers. Antimicrob Agents Chemother (2011) 1.06

Parasitological and clinical efficacy of standard treatment regimens against Plasmodium falciparum, P. vivax and P. malariae in Papua New Guinea. P N G Med J (2007) 1.05

A multiplex ligase detection reaction-fluorescent microsphere assay for simultaneous detection of single nucleotide polymorphisms associated with Plasmodium falciparum drug resistance. J Clin Microbiol (2006) 1.04

Quantifying the evolution and impact of antimalarial drug resistance: drug use, spread of resistance, and drug failure over a 12-year period in Papua New Guinea. J Infect Dis (2010) 1.00

Molecular analysis of Plasmodium falciparum from drug treatment failure patients in Papua New Guinea. Am J Trop Med Hyg (2004) 0.99

Studies on the epidemiology of malaria in New Guinea. Part II. Holoendemic malaria--the entomological picture. Trans R Soc Trop Med Hyg (1960) 0.97

Molecular assessment of Plasmodium falciparum resistance to antimalarial drugs in Papua New Guinea using an extended ligase detection reaction fluorescent microsphere assay. Antimicrob Agents Chemother (2010) 0.97

Global resistance surveillance: ensuring antimalarial efficacy in the future. Curr Opin Infect Dis (2009) 0.94

A mixed infection of vivax and falciparum malaria apparently resistant to 4-aminoquinoline: a case report. Trans R Soc Trop Med Hyg (1990) 0.93

A new high-throughput method for simultaneous detection of drug resistance associated mutations in Plasmodium vivax dhfr, dhps and mdr1 genes. Malar J (2011) 0.92

Different patterns of pfcrt and pfmdr1 polymorphisms in P. falciparum isolates from Nigeria and Brazil: the potential role of antimalarial drug selection pressure. Am J Trop Med Hyg (2012) 0.91

Differentiating Plasmodium falciparum alleles by transforming Cartesian X,Y data to polar coordinates. BMC Genet (2010) 0.87

High genetic diversity of Plasmodium vivax on the north coast of Papua New Guinea. Am J Trop Med Hyg (2013) 0.87

Chloroquine-resistant falciparum malaria in Papua New Guinea. Med J Aust (1976) 0.84

Temporal changes in Plasmodium falciparum anti-malarial drug sensitivity in vitro and resistance-associated genetic mutations in isolates from Papua New Guinea. Malar J (2015) 0.80